These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18302508)

  • 21. Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K.
    Morko J; Kiviranta R; Hurme S; Rantakokko J; Vuorio E
    Bone; 2005 May; 36(5):854-65. PubMed ID: 15826870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
    Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
    Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.
    Glover SJ; Eastell R; McCloskey EV; Rogers A; Garnero P; Lowery J; Belleli R; Wright TM; John MR
    Bone; 2009 Dec; 45(6):1053-8. PubMed ID: 19679211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)].
    Vahle JL; Zuehlke U; Schmidt A; Westmore M; Chen P; Sato M
    J Bone Miner Res; 2008 Dec; 23(12):2033-9. PubMed ID: 18684088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
    Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
    J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.
    Jiang Y; Zhao JJ; Mitlak BH; Wang O; Genant HK; Eriksen EF
    J Bone Miner Res; 2003 Nov; 18(11):1932-41. PubMed ID: 14606504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New therapeutical horizons in the management of postmenopausal osteoporosis.
    Migliaccio S; Fornari R; Greco EA; Di Luigi L; Lenzi A
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S117-9. PubMed ID: 24048905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts.
    Everts V; Hou WS; Rialland X; Tigchelaar W; Saftig P; Brömme D; Gelb BD; Beertsen W
    Calcif Tissue Int; 2003 Oct; 73(4):380-6. PubMed ID: 12874701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Both hPTH(1-34) and bFGF increase trabecular bone mass in osteopenic rats but they have different effects on trabecular bone architecture.
    Lane NE; Yao W; Kinney JH; Modin G; Balooch M; Wronski TJ
    J Bone Miner Res; 2003 Dec; 18(12):2105-15. PubMed ID: 14672345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of bisphosphonates on matrix mineralization.
    Boivin G; Meunier PJ
    J Musculoskelet Neuronal Interact; 2002 Dec; 2(6):538-43. PubMed ID: 15758388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.
    Sampath TK; Simic P; Sendak R; Draca N; Bowe AE; O'Brien S; Schiavi SC; McPherson JM; Vukicevic S
    J Bone Miner Res; 2007 Jun; 22(6):849-59. PubMed ID: 17352644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro.
    Morko J; Kiviranta R; Mulari MT; Ivaska KK; Väänänen HK; Vuorio E; Laitala-Leinonen T
    Bone; 2009 Apr; 44(4):717-28. PubMed ID: 19118660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
    McClung MR; San Martin J; Miller PD; Civitelli R; Bandeira F; Omizo M; Donley DW; Dalsky GP; Eriksen EF
    Arch Intern Med; 2005 Aug 8-22; 165(15):1762-8. PubMed ID: 16087825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
    Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
    J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parathyroid hormone as an anabolic therapy for women and men.
    Bilezikian JP; Rubin MR; Finkelstein JS
    J Endocrinol Invest; 2005; 28(8 Suppl):41-9. PubMed ID: 16329201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.